Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 24907233.
- Also identified by DOI 10.1212/WNL.0000000000000567 and PMC identifier 4117173.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Internuclear ophthalmoparesis (INO) in multiple sclerosis (MS) is due to demyelination of the medial longitudinal fasciculus (MLF) and provides an accessible model for studying consequences of raised body temperature and fatigue on central demyelination.<sup>1,2</sup> Prompted by one of our patient’s report of vision improvement after initiating dalfampridine, a potassium channel blocker prescribed for gait impairment,<sup>3</sup> we measured this drug's effects on 3 patients with MS with bilateral INO. All showed changes in horizontal saccadic conjugacy consistent with improved transmission of the neural pulse responsible for adducting movements.
Medical subject headings
- 4-Aminopyridine
- Multiple Sclerosis
- Ophthalmoplegia